
Philip Morris battles to buy a medical inhaler company
FT News Briefing
00:00
Philip Morris's Strategic Shift and Ethical Dilemmas in Industry Acquisition
This chapter examines Philip Morris's efforts to acquire a medical inhaler company as it seeks to pivot away from nicotine products. It highlights the controversies and ethical debates surrounding this move, particularly the pushback from anti-smoking advocates and the competition with a private equity firm.
Play episode from 03:34
Transcript


